PL3169341T3 - Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej - Google Patents

Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej

Info

Publication number
PL3169341T3
PL3169341T3 PL15738359T PL15738359T PL3169341T3 PL 3169341 T3 PL3169341 T3 PL 3169341T3 PL 15738359 T PL15738359 T PL 15738359T PL 15738359 T PL15738359 T PL 15738359T PL 3169341 T3 PL3169341 T3 PL 3169341T3
Authority
PL
Poland
Prior art keywords
expression
immune checkpoint
oncolytic virus
checkpoint modulators
modulators
Prior art date
Application number
PL15738359T
Other languages
English (en)
Polish (pl)
Inventor
Nathalie Silvestre
Michel Geist
Karola Rittner
Jean-Baptiste Marchand
Christine Thioudellet
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PL3169341T3 publication Critical patent/PL3169341T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/763—Herpes virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/765—Reovirus; Rotavirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/766—Rhabdovirus, e.g. vesicular stomatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/863—Poxviral vectors, e.g. entomopoxvirus
    • C12N15/8636—Vaccina virus vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1077—Pentosyltransferases (2.4.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/02—Pentosyltransferases (2.4.2)
    • C12Y204/02009—Uracil phosphoribosyltransferase (2.4.2.9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01023—Ceramidase (3.5.1.23)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL15738359T 2014-07-16 2015-07-16 Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej PL3169341T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14306153 2014-07-16
EP15738359.7A EP3169341B1 (en) 2014-07-16 2015-07-16 Oncolytic virus for expression of immune checkpoint modulators
PCT/EP2015/066263 WO2016008976A1 (en) 2014-07-16 2015-07-16 Oncolytic virus for expression of immune checkpoint modulators

Publications (1)

Publication Number Publication Date
PL3169341T3 true PL3169341T3 (pl) 2019-12-31

Family

ID=51220528

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15738359T PL3169341T3 (pl) 2014-07-16 2015-07-16 Wirus onkolityczny do ekspresji modulatorów punktu kontroli immunologicznej

Country Status (14)

Country Link
US (2) US10555981B2 (cg-RX-API-DMAC7.html)
EP (2) EP3552615B8 (cg-RX-API-DMAC7.html)
JP (2) JP6895374B2 (cg-RX-API-DMAC7.html)
CN (2) CN107208069A (cg-RX-API-DMAC7.html)
AU (2) AU2015289125B2 (cg-RX-API-DMAC7.html)
CA (2) CA3190510A1 (cg-RX-API-DMAC7.html)
DK (2) DK3169341T3 (cg-RX-API-DMAC7.html)
ES (2) ES2909957T3 (cg-RX-API-DMAC7.html)
HU (1) HUE045108T2 (cg-RX-API-DMAC7.html)
IL (1) IL250058A0 (cg-RX-API-DMAC7.html)
PL (1) PL3169341T3 (cg-RX-API-DMAC7.html)
PT (1) PT3169341T (cg-RX-API-DMAC7.html)
RU (1) RU2696312C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016008976A1 (cg-RX-API-DMAC7.html)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114984062A (zh) * 2012-08-30 2022-09-02 安姆根有限公司 使用单纯疱疹病毒和免疫检查点抑制剂治疗黑色素瘤的方法
AU2014361473B2 (en) 2013-12-12 2019-09-26 Jiangsu Hengrui Medicine Co., Ltd. PD-1 antibody, antigen-binding fragment thereof, and medical application thereof
JP6843736B2 (ja) * 2014-07-16 2021-03-17 トランジェーヌＴｒａｎｓｇｅｎｅ 腫瘍溶解性ウイルスと免疫チェックポイントモジュレーターとの組合せ
CA3190510A1 (en) * 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CA3003133C (en) 2014-10-24 2020-09-15 StemImmune, Incorporated Combination immunotherapy approach for treatment of cancer
WO2016144564A2 (en) 2015-02-25 2016-09-15 Memorial Sloan-Kettering Cancer Center Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors
EP3283088A4 (en) 2015-04-17 2018-10-24 Memorial Sloan-Kettering Cancer Center Use of mva or mvadeltae3l as immunotherapeutic agents against solid tumors
SI3283508T1 (sl) 2015-04-17 2021-09-30 Alpine Immune Sciences, Inc. Imunomodulirajoči proteini z nastavljivimi afinitetami
RS60792B1 (sr) 2015-05-29 2020-10-30 Agenus Inc Anti-ctla-4 antitela i postupci za njihovu primenu
WO2017004165A1 (en) * 2015-06-29 2017-01-05 Regents Of The University Of Minnesota Apobec3b mutagenesis and immunotherapy
JP2018527895A (ja) 2015-06-29 2018-09-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 抗−ａｐｏｂｅｃ３抗体並びにその製造及び使用方法
HK1250033A1 (zh) 2015-07-13 2018-11-23 Cytomx Therapeutics Inc. 抗-pd-1抗体、可活化的抗-pd-1抗体、及其使用方法
EA201800148A1 (ru) 2015-08-11 2019-01-31 Калиди Биотерапьютикс, Инк. Оспенная вакцина для лечения рака
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
CN109069486A (zh) 2015-12-14 2018-12-21 X4 制药有限公司 治疗癌症的方法
PT3393468T (pt) 2015-12-22 2023-01-19 X4 Pharmaceuticals Inc Métodos para tratar imunodeficiências
EP3400293B2 (en) 2016-01-08 2023-07-12 Replimune Limited Modified oncolytic virus
CA3010617A1 (en) * 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
AU2017212713B2 (en) 2016-01-27 2023-01-19 Oncorus, Inc. Oncolytic viral vectors and uses thereof
EP3419662A4 (en) 2016-02-25 2019-09-18 Memorial Sloan Kettering Cancer Center HUMAN FLT3L EXPRESSIVE RECOMBINANT MVA OR MVADELE3L AND USE THEREOF AS IMMUNOTHERAPEUTICS AGAINST SOLID TUMORS
CA3015650A1 (en) 2016-02-25 2017-08-31 Memorial Sloan Kettering Cancer Center Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
SG11201808457PA (en) 2016-04-15 2018-10-30 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof
US11414491B2 (en) 2016-05-18 2022-08-16 Mayo Foundation For Medical Education And Research Targeting PD-L1 on tumor cells
CN109641838A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223239A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10988465B2 (en) 2016-06-21 2021-04-27 X4 Pharmaceuticals, Inc. CXCR4 inhibitors and uses thereof
RU2021127872A (ru) * 2016-06-30 2021-11-09 Онкорус, Инк. Доставка терапевтических полипептидов посредством псевдотипированных онколитических вирусов
US20190367886A1 (en) * 2016-07-13 2019-12-05 National University Corporation Tottori Tottori University Method for producing vaccinia virus expressing foreign gene
US20220354888A1 (en) * 2016-08-03 2022-11-10 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
TW201825674A (zh) * 2016-09-09 2018-07-16 美商艾斯合顧問有限公司 表現雙特異性接合分子的溶瘤病毒
EP3534923A4 (en) * 2016-11-01 2020-05-27 DNAtrix, Inc. COMBINATION THERAPY FOR THE TREATMENT OF BRAIN CARCINOMAS
MD3551660T2 (ro) 2016-12-07 2024-03-31 Agenus Inc Anticorpi anti-CTLA-4 și procedee de utilizare a acestora
AU2017375958A1 (en) * 2016-12-12 2019-07-04 Multivir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
CN108261426B (zh) 2017-01-04 2019-04-05 杭州康万达医药科技有限公司 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用
GB201700350D0 (en) * 2017-01-09 2017-02-22 Replimune Ltd Altered virus
BR112019015514A2 (pt) * 2017-01-30 2020-04-07 Epicentrx Inc mutantes de tata-box e caat-box seletivos de tumor
JP6874147B2 (ja) * 2017-02-28 2021-05-19 ジーンメディスン・カンパニー・リミテッド 腫瘍特異的殺傷アデノウイルスおよび免疫チェックポイント阻害剤を含む抗癌用組成物
EP3621646A4 (en) 2017-05-12 2021-06-02 Memorial Sloan Kettering Cancer Center USEFUL VACCINE VIRUS MUTANTS FOR ANTI-CANCER IMMUNOTHERAPY
JP7187486B2 (ja) 2017-05-25 2022-12-12 レイドス， インコーポレイテッド Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド
RU2771110C2 (ru) 2017-07-26 2022-04-26 Онкорус, Инк. Онколитические вирусные векторы и их применение
CN109576231B (zh) * 2017-09-28 2022-03-25 北京康万达医药科技有限公司 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途
EP3694870A1 (en) 2017-10-10 2020-08-19 Alpine Immune Sciences, Inc. Ctla-4 variant immunomodulatory proteins and uses thereof
MY203416A (en) 2017-10-18 2024-06-27 Alpine Immune Sciences Inc Variant icos ligand immunomodulatory proteins and related compositions and methods
SG11202002123XA (en) * 2017-10-27 2020-04-29 Merck Sharp & Dohme Compositions and methods for treating liver cancer
CN111712250A (zh) * 2017-11-16 2020-09-25 复诺健生物科技加拿大有限公司 靶向部分修饰的溶瘤病毒
CN108165536A (zh) * 2017-12-11 2018-06-15 浙江大学 一种重组溶瘤痘苗病毒及其制备方法与应用
EP3731850A4 (en) 2017-12-29 2021-12-01 Oncorus, Inc. ONCOLYTIC VIRUS DELIVERY OF THERAPEUTIC POLYPEPTIDES
BR112020013236A2 (pt) 2018-01-03 2020-12-01 Alpine Immune Sciences, Inc. proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
MX2020007010A (es) 2018-01-05 2020-12-10 Ottawa Hospital Res Inst Vectores modificados de orthopoxvirus.
BR112020014727A2 (pt) * 2018-01-19 2020-12-08 Kolon Life Science, Inc. Vírus vaccinia recombinante e composição farmacêutica compreendendo o mesmo
WO2019148109A1 (en) * 2018-01-26 2019-08-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Expression of metabolic modulators in tumor microenvironment to improve tumor therapy
WO2019151836A1 (en) * 2018-02-05 2019-08-08 Sillajen, Inc. Oncolytic vaccinia virus expressing an immune checkpoint protein antagonist to treat cancer
JP7167395B2 (ja) * 2018-02-28 2022-11-09 バイオノックス インコーポレイテッド 有効成分として抗がんウイルス及びヒドロキシウレアを含むがんを予防又は治療するための医薬組成物
CN108329378B (zh) * 2018-03-12 2020-09-25 华中农业大学 塞内卡谷病毒vp1蛋白、编码基因、杂交瘤细胞株和单克隆抗体及其应用
SG11202008589TA (en) * 2018-03-13 2020-10-29 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
CN112020510B (zh) 2018-03-19 2024-10-11 茂体外尔公司 包含用于治疗癌症的肿瘤抑制基因疗法和cd122/cd132激动剂的方法及组合物
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
WO2019241758A1 (en) 2018-06-15 2019-12-19 Alpine Immune Sciences, Inc. Pd-1 variant immunomodulatory proteins and uses thereof
CN112771157A (zh) * 2018-08-16 2021-05-07 Musc研究发展基金会 重组黏液瘤病毒及其用途
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN113164538B (zh) * 2018-09-10 2025-03-04 上海锦斯生物技术有限公司 修饰的溶瘤病毒、其组合物和用途
BR112021004692A2 (pt) 2018-09-15 2021-06-08 Memorial Sloan Kettering Cancer Center poxvírus recombinantes para imunoterapia de câncer
CN111100846A (zh) 2018-10-26 2020-05-05 上海元宋生物技术有限公司 表达pd-1结合蛋白的溶瘤病毒及其应用
BR112021008263A2 (pt) * 2018-10-31 2021-08-10 Humanigen, Inc. materiais e métodos para tratamento de câncer
KR20210087029A (ko) * 2018-11-01 2021-07-09 바이오인벤트 인터내셔날 에이비 신규한 길항작용 항 tnfr2 항체 분자
KR20210091740A (ko) * 2018-11-06 2021-07-22 카리디 바이오테라퓨틱스, 인크. 세포-매개된 종양용해 바이러스 요법용 향상된 시스템
CN113227361B (zh) 2018-11-21 2024-12-20 梅奥医学教育及研究基金会 腺病毒和使用腺病毒的方法
CN109627336A (zh) * 2018-12-20 2019-04-16 南京昂科利医药科技创新研究院有限公司 一种表达pd-l1单链抗体的新城疫溶瘤病毒的制备方法及应用
AU2019410148A1 (en) * 2018-12-21 2021-08-12 Ottawa Hospital Research Institute Modified orthopoxvirus vectors
AU2019412516A1 (en) 2018-12-28 2021-07-15 Transgene M2-defective poxvirus
CA3125370A1 (en) * 2019-01-29 2020-08-06 Arno Thaller Recombinant oncolytic newcastle disease viruses with increased activity
CN109913425B (zh) * 2019-03-22 2021-05-11 中国人民解放军总医院第五医学中心 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用
CA3134140A1 (en) * 2019-03-28 2020-10-01 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Oncolytic myxoma virus expressing fast p14 to treat hematological cancer
EP3911671A1 (en) 2019-04-29 2021-11-24 Mayo Foundation for Medical Education and Research Multivalent pd-l1 binding compounds for treating cancer
US11407829B2 (en) 2019-05-22 2022-08-09 Leidos, Inc. LAG3 binding peptides
CA3147640A1 (en) 2019-07-19 2021-01-28 The Trustees Of Columbia University In The City Of New York Second generation seneca valley virus oncolytic therapy: compositions and methods thereof
WO2021040064A1 (ko) * 2019-08-26 2021-03-04 주식회사 바이오녹스 백시니아 바이러스 및 히드록시유레아를 유효성분으로 포함하는 암 치료용 약학 조성물
AU2020402303A1 (en) * 2019-12-12 2022-06-09 Ignite Immunotherapy, Inc. Variant oncolytic vaccinia virus and methods of use thereof
AU2021224730A1 (en) * 2020-02-20 2022-09-22 Musc Foundation For Research Development Recombinant myxoma viruses and uses thereof
WO2021183650A1 (en) 2020-03-10 2021-09-16 X4 Pharmaceuticals, Inc. Methods for treating neutropenia
JP2023529186A (ja) * 2020-06-05 2023-07-07 上海宝済薬業有限公司 酵素とウィルスとの薬物組成物及びその使用
WO2022026496A2 (en) 2020-07-31 2022-02-03 Leidos, Inc. Lag3 binding peptides
US11987646B2 (en) 2020-10-12 2024-05-21 Leidos, Inc. Immunomodulatory peptides
CA3197069A1 (en) * 2020-10-13 2022-04-21 Immunovaccine Technologies Inc. Methods of treating diffuse large b-cell lymphoma
JPWO2022107705A1 (cg-RX-API-DMAC7.html) * 2020-11-17 2022-05-27
CN112641798A (zh) * 2020-12-29 2021-04-13 武汉博威德生物技术有限公司 一种提高重组柯萨奇病毒溶瘤作用的方法
AU2022205429A1 (en) * 2021-01-11 2023-07-20 Seneca Therapeutics, Inc. Seneca valley virus combination therapy to treat a cancer refractory to a checkpoint inhibitor
CA3207261A1 (en) * 2021-01-19 2022-07-28 Seneca Therapeutics, Inc. Armed seneca valley virus oncolytic therapy compositions and methods thereof
CN117177763A (zh) * 2021-02-02 2023-12-05 吉奥瓦科斯公司 用于增强疫苗接种期间的t细胞启动的病毒构建体
CA3209252A1 (en) * 2021-02-26 2022-09-01 Sillajen, Inc. Oncolytic virus and uses thereof
CN114934065A (zh) * 2021-11-25 2022-08-23 浙江理工大学绍兴生物医药研究院有限公司 携带免疫检查点分子tim-3抗体基因的溶瘤腺病毒构建方法和应用
CN120648657A (zh) * 2024-03-08 2025-09-16 上海锦斯生物技术有限公司 一种修饰的溶瘤病毒及其组合物

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
FR2656800B1 (fr) 1990-01-08 1992-05-15 Roussy Inst Gustave Nouvelles proteines produits par les lymphocytes humains, sequence d'adn codant pour ces proteines et applications pharmaceutiques et biologiques.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
FR2751343B1 (fr) 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
EP0988053A1 (en) 1997-06-11 2000-03-29 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
ES2282133T3 (es) 1999-08-24 2007-10-16 Medarex, Inc. Anticuerpos frente a la ctla-4 humano y sus usos.
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1263461A4 (en) 2000-03-07 2009-08-12 Merck & Co Inc ADENOVIRUS FORMULATIONS
US20040241745A1 (en) 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
GB0128288D0 (en) 2001-11-27 2002-01-16 Siddall & Hilton Ltd Spring location means
EP1418942B1 (en) 2001-12-10 2005-08-03 Bavarian Nordic A/S Poxvirus-containing compositions and process for their preparation
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
NZ536746A (en) 2002-06-13 2007-02-23 Crucell Holland Bv An agonistic antibody or fragment thereof that immunospecifically binds and stimulates the human OX40-receptor
US7595048B2 (en) 2002-07-03 2009-09-29 Ono Pharmaceutical Co., Ltd. Method for treatment of cancer by inhibiting the immunosuppressive signal induced by PD-1
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
JP4511943B2 (ja) 2002-12-23 2010-07-28 ワイス エルエルシー Ｐｄ−１に対する抗体およびその使用
CN1826410B (zh) 2003-07-21 2011-10-26 特兰斯吉恩股份有限公司 具有改良的胞嘧啶脱氨酶活性的多肽
EP1528101A1 (en) 2003-11-03 2005-05-04 ProBioGen AG Immortalized avian cell lines for virus production
AU2005303912B2 (en) 2004-11-12 2011-02-17 Bayer Schering Pharma Aktiengesellschaft Recombinant Newcastle Disease Virus
FR2884255B1 (fr) 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
NZ601439A (en) 2005-06-08 2012-11-30 Brigham & Womens Hospital Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1) pathway
KR101357685B1 (ko) 2005-11-21 2014-02-06 사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 재조합 바이러스용 안정화 제형
JP6092497B2 (ja) 2006-03-30 2017-03-08 ユニバーシティー オブ カリフォルニア 抗ｃｔｌａ−４抗体の限局性分泌のための方法および組成物
BRPI0712158B8 (pt) 2006-06-20 2021-05-25 Transgene Sa processo para produzir uma composição de poxvírus de tipo selvagem, atenuado e/ou recombinante sem especificidade de infecção visada
AU2007263281B2 (en) 2006-06-20 2012-12-06 Transgene S.A. Recombinant viral vaccine
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP1985305A1 (en) 2007-04-24 2008-10-29 Vivalis Duck embryonic derived stem cell lines for the production of viral vaccines
NZ578960A (en) 2007-05-14 2012-11-30 Bavarian Nordic As Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
US20090028857A1 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
US9687515B2 (en) * 2007-11-19 2017-06-27 Transgene S.A. Poxviral oncolytic vectors
PL2212345T3 (pl) * 2007-11-19 2016-07-29 Transgene Sa Onkolityczne wektory pokswirusowe
RU2508401C2 (ru) 2007-11-19 2014-02-27 Трансжене С.А. Поксвирусные онколитические векторы
TW200938221A (en) 2007-11-30 2009-09-16 Abbott Lab Protein formulations and methods of making same
CN102257134B (zh) 2008-02-12 2014-03-05 赛诺菲巴斯德有限公司 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8470977B2 (en) 2008-03-14 2013-06-25 Transgene S.A. Antibody against the CSF-1R
CN102740881A (zh) 2009-05-12 2012-10-17 特兰斯吉恩股份有限公司 正痘病毒产生和纯化方法
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
CN103732236B (zh) 2011-08-05 2017-09-15 新罗杰公司 用于生产痘苗病毒的方法和组合物
US20130071403A1 (en) 2011-09-20 2013-03-21 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR20150038066A (ko) 2012-07-30 2015-04-08 알렉스 와 힌 영 종양 세포, 암세포파괴 바이러스 벡터 및 면역 체크포인트 조절인자를 갖는 암 백신 시스템
US20150250837A1 (en) * 2012-09-20 2015-09-10 Morningside Technology Ventures Ltd. Oncolytic virus encoding pd-1 binding agents and uses of the same
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
CA3190510A1 (en) * 2014-07-16 2016-01-21 Transgene Sa Oncolytic virus for expression of immune checkpoint modulators
CN108165536A (zh) * 2017-12-11 2018-06-15 浙江大学 一种重组溶瘤痘苗病毒及其制备方法与应用
SG11202008589TA (en) * 2018-03-13 2020-10-29 Memorial Sloan Kettering Cancer Center Oncolytic vaccinia virus expressing immune checkpoint blockade for cancer immunotherapy
EP3617230A1 (en) * 2018-09-03 2020-03-04 BioInvent International AB Novel antibodies and nucleotide sequences, and uses thereof
CN110218707B (zh) * 2019-05-29 2021-10-22 上海市公共卫生临床中心 一种新型溶瘤病毒及其制备方法和应用

Also Published As

Publication number Publication date
EP3552615B1 (en) 2022-01-26
DK3552615T3 (da) 2022-02-14
ES2743873T3 (es) 2020-02-21
WO2016008976A1 (en) 2016-01-21
RU2017103162A3 (cg-RX-API-DMAC7.html) 2018-08-22
JP2017522025A (ja) 2017-08-10
EP3552615B8 (en) 2022-03-02
EP3169341A1 (en) 2017-05-24
ES2909957T3 (es) 2022-05-11
US20200197457A1 (en) 2020-06-25
AU2015289125B2 (en) 2019-11-28
JP7077377B2 (ja) 2022-05-30
IL250058A0 (en) 2017-03-30
US20170157188A1 (en) 2017-06-08
AU2015289125A1 (en) 2017-02-02
CA3190510A1 (en) 2016-01-21
EP3552615A1 (en) 2019-10-16
AU2020200541B2 (en) 2021-12-16
HUE045108T2 (hu) 2019-12-30
JP6895374B2 (ja) 2021-06-30
PT3169341T (pt) 2019-09-09
CA2954841A1 (en) 2016-01-21
AU2020200541A1 (en) 2020-02-13
JP2021006048A (ja) 2021-01-21
CN120555373A (zh) 2025-08-29
EP3169341B1 (en) 2019-06-05
US10555981B2 (en) 2020-02-11
RU2017103162A (ru) 2018-08-16
DK3169341T3 (da) 2019-08-05
CN107208069A (zh) 2017-09-26
US11779619B2 (en) 2023-10-10
RU2696312C2 (ru) 2019-08-01

Similar Documents

Publication Publication Date Title
IL250058A0 (en) Oncolytic virus for expression of immune checkpoint modulators
IL250103B (en) Combination of an oncolytic virus with immune checkpoint modulators
IL285287A (en) Antibodies to tigit
IL260480B (en) Oncolytic virus modifications
GB201405834D0 (en) Oncolytic virus
IL249449B (en) Antibodies to cd127
GB202014322D0 (en) Virtualization of tangible interface objects
GB201406608D0 (en) Virus
GB2526680B (en) Runway arrangement
GB201419572D0 (en) Virus
TWM490072U (en) Cloud development system of application system
SG11201607445QA (en) Methods of modulating wars2
GB2532101B (en) Time of flight detection system
GB201522317D0 (en) Chimeric oncolytic virus
GB201621665D0 (en) Chimeric oncolytic virus
GB201408046D0 (en) Virus preparations
GB201406470D0 (en) Virus
GB201403582D0 (en) Virus
GB201415715D0 (en) Suspension Of Materials
GB201416054D0 (en) Chemotherapy of viruses
AU2014903991A0 (en) Genetically stable oncolytic virus